Purpose OSI-930 is a book, potent, oral small-molecule receptor tyrosine kinase inhibitor, predominantly against VEGF receptors (VEGFR), c-Kit, and platelet-derived development element receptors. GCIG CA125 response (= 1)]. Eleven of 19 greatly pretreated imatinib-resistant individuals with gastrointestinal stromal tumors accomplished RECIST steady disease (median duration: 126 times), with FDG-PET scans displaying PRs in 4 of… Continue reading Purpose OSI-930 is a book, potent, oral small-molecule receptor tyrosine kinase